Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
AssigneeNGM Biopharmaceuticals, Inc.
InventorsAlexander Mark DePaoli, Lei Ling
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder.
Claims36
A method of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising:
- (A) a) administering a chimeric peptide sequence, comprising:
- i) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122), and
- ii) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 (FGF19), WGDPRLRHLYTSG (SEQ ID NO:169), wherein the W residue corresponds to the first amino acid position of the C-terminal region;
- and
- b) administering at least one additional agent effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder, or
- (B) a) administering a chimeric peptide sequence, comprising:
- i) an N-terminal region comprising a portion of SEQ ID NO:100 (FGF21), the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises amino acid residues GQV, and wherein the V residue corresponds to the last amino acid position of the N-terminal region, and
- ii) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 21-29 of SEQ ID NO:99 (FGF19), RLRHLYTSG (SEQ ID NO:185), and wherein the R residue corresponds to the first position of the C-terminal region and
- b) administering at least one additional agent effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder,
- thereby modulating bile acid homeostasis or treating the bile acid-related or associated disorder.
(canceled)
A method of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising:
- a) administering a chimeric peptide sequence, comprising:
- i) an N-terminal region comprising a portion of SEQ ID NO:100 (FGF21), the N-terminal region having a first amino acid position and a last amino acid position,
- wherein the N-terminal region comprises at least 5 contiguous amino acids of SEQ ID NO:100 (FGF21) including the amino acid residues GQV, and wherein the V residue corresponds to the last amino acid position of the N-terminal region, and
- ii) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 21-29 of SEQ ID NO:99 (FGF19), RLRHLYTSG (SEQ ID NO:185), and wherein the R residue corresponds to the first position of the C-terminal region;
- and
- b) administering at least one additional agent effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder,
- thereby modulating bile acid homeostasis or treating the bile acid-related or associated disorder.
(canceled)
A method of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising:
- a) administering a peptide sequence, wherein the peptide sequence comprises or consists of any of:
- i) a FGF19 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19;
- ii) a FGF21 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF21;
- iii) a portion of an FGF19 sequence fused to a portion of an FGF21 sequence;
- or
- iv) a portion of an FGF19 sequence fused to a portion of an FGF21 sequence, wherein the FGF19 and/or FGF21 sequence portion(s) have one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19 and/or FGF21,
- wherein optionally the reference or wild type FGF19 sequence is set forth as:
- (SEQ ID NO:
- 99)
- RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCAR
- GQSAHSLLEIVAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAF
- EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMV
- PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK;
- and/or
- the reference or wild type FGF21 sequence is set forth as:
- (SEQ ID NO:
- 100)
- RHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSP
- ESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELL
- LEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEP
- PGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS;
- and
- b) administering at least one additional agent effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder,
- thereby modulating bile acid homeostasis or treating the bile-acid related or associated disorder.
(canceled)
-25. (canceled)
-31. (canceled)
-39. (canceled)
-45. (canceled)
-51. (canceled)
-54. (canceled)
-59. (canceled)
-71. (canceled)
-75. (canceled)
-125. (canceled)
Dependencies are inferred from the claim text.